This article is more than 5 years old. Information may no longer be current.
Inhibition of radiographic progression independent of disease activity for adalimumab in PsA
Click Here to Manage Email Alerts
MADRID — Inhibition of radiographic progression was independent of disease activity for adalimumab in patients with psoriatic arthritis, according to findings presented at the EULAR Annual Congress.
“There was less radiographic progression in patients treated with adalimumab compared to patients treated with placebo,” Robert Landewe, MD, from the University of Amsterdam, said. “Across all different disease activity categories with significant differences in patients with moderate and high disease activity, radiographic progression still correlated moderately well with disease activity in patients treated with placebo, but did not in patients treated with adalimumab.” He added, the findings, “support a disconnect phenomenon following adalimumab treatment.”
Landewe and colleagues performed a 24-week randomized, double-blind trial of 296 patients who received either adalimumab or placebo.
They found a higher proportion of the adalimumab group achieved minimal disease activity or remission compared with patients who received placebo. In addition, the adalimumab group had a significantly lower modified total Sharp score, even in those with high disease activity. With respect to radiographic progression, there was an interaction between treatment and status of disease activity. Furthermore, radiographic progression was linked with disease activity status in the placebo group, but not in the adalimumab group. — by Will Offit
Reference:
Landewe R, et al. Abstract #OP0108. Presented at: EULAR Annual Congress; June 14-17, 2017; Madrid.
Disclosure: Landewe reports he received grant and research support from Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB and Wyeth; was a consultant for Abbott/AbbVie, Ablynx, Amgen, AstraZeneca, BMS, Janssen, GSK, Merck, Novo-Nordisk, Novartis, Pfizer, Roche, Schering-Plough, TiGenics, UCB and Wyeth; is the director of rheumatology consultancy for BV; and is on the speakers bureau for Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB and Wyeth.